7150-23-4

中文名称 6-甲氧基-3-吡啶羧胺

英文名称 BUTTPARK 182\12-94

CAS 7150-23-4

分子式 C7H8N2O2

分子量 152.15

MOL 文件 7150-23-4.mol

更新日期 2024/07/09 19:53:28

7150-23-4 结构式

基本信息物理化学性质安全数据 6-甲氧基-3-吡啶羧胺价格(试剂级) 常见问题列表

基本信息

中文别名

6-甲氧基-3-吡啶羧胺
6-甲氧基-3-吡啶甲酰胺

英文别名

JBSNF-000088
BUTTPARK 182\12-94
6-Methoxynicotinamide
JBSNF-000088 (JBSNF000088
6-methoxy-3-pyridinecarboxamide
6-METHOXYPYRIDINE-3-CARBOXAMIDE
3-PYRIDINECARBOXAMIDE, 6-METHOXY-

所属类别

生物化工：抑制剂

物理化学性质

熔点178-180°C

沸点301.6±22.0 °C(Predicted)

密度1.213±0.06 g/cm3(Predicted)

储存条件-20°C冷冻

溶解度可溶于DMSO（少许）、甲醇（少许）

酸度系数(pKa)15.17±0.50(Predicted)

形态固体

颜色灰白色至浅米色

InChIInChI=1S/C7H8N2O2/c1-11-6-3-2-5(4-9-6)7(8)10/h2-4H,1H3,(H2,8,10)

InChIKeyKXDSMFBEVSJYRF-UHFFFAOYSA-N

SMILESC1=NC(OC)=CC=C1C(N)=O

安全数据

危险性符号(GHS)

GHS07

警示词警告

危险性描述H302-H315-H319-H335

防范说明P261-P305+P351+P338

海关编码2933399990

6-甲氧基-3-吡啶羧胺价格(试剂级)

报价日期	产品编号	产品名称	CAS号	包装	价格
2024/04/30	XW02715023401	6-甲氧基-3-吡啶羧胺	7150-23-4	100MG	44元
2024/04/30	XW02715023402	6-甲氧基-3-吡啶羧胺	7150-23-4	250MG	106元
2024/04/30	S6779	6-甲氧基-3-吡啶羧胺 JBSNF-000088	7150-23-4	25mg	470.74元

常见问题列表

生物活性

JBSNF-000088 (6-Methoxynicotinamide)是一种烟酰胺（NA）的类似物，是 Nicotinamide N-methyltransferase (NNMT) 的有效抑制剂，对 human NNMT(hNNMT)、monkey NNMT (mkNNMT) 和 mouse NNMT (mNNMT)的IC50值为1.8 µM、2.8 µM 和 5.0 µM。

靶点

Target	Value
hNNMT (Cell-free assay)	1.8 μM
mkNNM (Cell-free assay)	2.8 μM
mNNMT (Cell-free assay)	5.0 μM

体外研究

JBSNF-000088 (6-Methoxynicotinamide) has IC ₅₀ values are 1.6 and 6.3 µM for U2OS or differentiated 3T3L1 cells.

体内研究

JBSNF-000088 (6-Methoxynicotinamide) (50 mg/kg; oral route of administration for four weeks) shows statistically significant reduction in body weight (%) and leads to a statistically significant reduction in fed blood glucose on day 21.
JBSNF-000088 (50 mg/kg; oral gavage administration; twice daily for four weeks) leads to a statistically significant improvement in oral glucose tolerance on day 28 with glucose tolerance being normalized.
JBSNF-000088 (1 mg/kg; intravenous administration; for 4 hours) results in low plasma clearance of 21 mL/min▪kg and the volume of distribution at steady state of 0.7 L/kg, a very short plasma half-life of 0.5 hours upon intravenous administration.
JBSNF-000088 (10 mg/kg; oral gavage; for 4 hours) results in a Cmax of 3568 ng/mL with a T _max value of 0.5 hours, indicating rapid absorption in the intestine, and half-life of 0.4 hours by oral gavage. The oral bioavailability is found to be approximately 40%.

Animal Model:	Mice with high fat diet (HFD)-induced obesity
Dosage:	50 mg/kg
Administration:	Oral route of administration for four weeks; oral gavage administration and twice daily for four weeks
Result:	Showed statistically significant reduction in body weight (%) and led to a statistically significant reduction in fed blood glucose on day 21 by oral route of administration. Led to a statistically significant improvement in oral glucose tolerance on day 28 with glucose tolerance being normalized by oral gavage administration.

Animal Model:	C57BL/6 mice
Dosage:	1 mg/kg (Intravenous administration);10 mg/kg (oral gavage)(Pharmacokinetic Study)
Administration:	Intravenous administration and oral gavage; for 4 hours
Result:	Resulted in low plasma clearance of 21 mL/min▪kg and the volume of distribution at steady state of 0.7 L/kg, a very short plasma half-life of 0.5 h upon intravenous administration. Resulted in a Cmax of 3568 ng/mL with a T _max value of 0.5 hours, indicating rapid absorption in the intestine, and half-life of 0.4 hours by oral gavage.